Net sales and operating profit were 1% below consensus (Refinitiv) in Q3.
Q3 EBIT of SEK 33m, 25% below ABGSC forecast AUM up 6% q-o-q, strengthen by Aquila Group transaction...
Redeye returns with more flesh on the bones and presents its estimate changes on the back of the Q3 ...
We lower '23e-'25e adj. EBITA by 5-1% B3's lowered '25 targets offset by cost-savings programme '23e...
Redeye makes minor revisions based on the Q3 report.
Redeye thinks the Q3 report was weaker than expected.
Redeye provides an update subsequently Gapwaves Q3 2023 report.
Redeye comments on the third quarter report of BioInvent.
Redeye sees a Q3 report that roughly matched our expectations and was in line with Management’s guid...
Redeye provides an update following the Q3 report. The rolling 12-month net sales increased by 16.
Redeye thinks the Q3 report was good, and in line with what the company had previously indicated.
Redeye updates on Evolution following its Q3-results which came in slightly below our forecast.
Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and s...
Fiskars pre-released Q3 headline figures on 12 October.
Q3: Large volume-driven beat Pulp prices on the rise Fair value range: SEK 9-16/sh Q3: Figures well...
NAV +1.2%, up 13 quarters in a row YTD outperformance vs.
A poor quarter, but Q4e should be better Adj. EBITA down 4-5% for '23e-'25e 14x '24e EV/EBITA, 19% '...
Q3: solid organic growth and strong margin improvement Positive revisions continue on further proof ...
4.5% organic sales growth y-o-y EBITA margin flat y-o-y adj.
48% organic growth in Q3 and solid order intake We raise sales estimates 4% and leave EBIT unchanged...
